Personalized neck radiation for nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests whether giving radiation only to the specific lymph nodes that need it works as well as standard radiation for people with nasopharyngeal cancer. It aims to reduce side effects while still controlling the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be newly diagnosed with nasopharyngeal cancer and not have received any treatment yet.
- The cancer must not have spread to other parts of the body.
- You must be between 18 and 70 years old.
- Your general health must be good, with a performance status score above 70.
- Your blood counts (white cells, red cells, and platelets) must be within a certain range.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of radiation therapy that adjusts in real-time to treat nasopharyngeal cancer. It is for people who have not received prior radiation and have no distant spread of cancer.
This Phase 2 study tests whether using a special scan (PET/CT) to guide radiation can safely reduce the radiation dose for people with nasopharyngeal cancer. It may help lessen side effects while still treating the cancer effectively.
This study tests if giving a lower dose of radiation to the neck area (where the cancer hasn't spread) is just as safe and effective as the standard dose in people with nasopharyngeal cancer. The goal is to reduce side effects while maintaining cancer control.
This trial tests a new way to plan radiation treatment for nasopharyngeal cancer, where the target area is tailored to each patient's tumor spread. It aims to improve effectiveness while reducing side effects.
This trial tests whether a smaller radiation treatment area is as effective as the usual larger one for people whose metastatic nasopharyngeal cancer has responded well to first-line chemotherapy plus immunotherapy. It aims to reduce side effects while keeping the cancer under control.
This trial tests a new treatment for nasopharyngeal cancer that adds an immune-boosting drug (toripalimab) before and after radiation therapy, while skipping radiation to the neck lymph nodes. It aims to see if this approach is effective and reduces side effects.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.